Press Releases
Search
-
22 Aug 2022
Antimicrobial Resistance
The SPECIFIC REVEAL® Rapid AST System has received Breakthrough Device Designation from the U.S. Food and Drug Administration
bioMérieux, a world leader in the field of in vitro diagnostics, today announces that the U.S. Food and Drug Administration (FDA) has granted its Breakthrough Device Designation for the SPECIFIC REVEAL® Rapid Antimicrobial Susceptibility Test (AST) System.
-
28 Jul 2022
Business & Solutions
bioMérieux receives FDA Clearance for NEPHROCHECK® test on VIDAS®
bioMérieux announced the FDA Clearance of VIDAS® NEPHROCHECK® assay to detect kidney stress in patients at risk of acute kidney injury (AKI).
-
07 Jul 2022
Pharma Quality Control
bioMérieux launches 3P® ENTERPRISE, an innovative solution for the pharma industry
bioMérieux, a world leader in the field of in vitro diagnostics, launches 3P® ENTERPRISE, an innovative solution designed to ensure environmental monitoring processes are fully efficient and under control at all times.
-
06 Jul 2022
Antimicrobial Resistance
Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
Boehringer Ingelheim, Evotec SE and bioMérieux announced today that they have formed a joint venture to create the next generation of antimicrobials along with actionable diagnostics to fight Antimicrobial Resistance (AMR).
-
19 May 2022
Antimicrobial Resistance
Closing of the acquisition of Specific Diagnostics
bioMérieux, a world leader in the field of in vitro diagnostics, announces that it has finalized the acquisition of Specific Diagnostics, a privately held U.S. based company that has developed a rapid antimicrobial susceptibility test (AST) system that delivers phenotypic AST directly from positive blood cultures.
-
13 May 2022
Business & Solutions
bioMérieux announces the CE marking of VIDAS® tests for Chikungunya virus diagnosis
bioMérieux, a world leader in the field of in vitro diagnostics, announces the CE marking of its automated tests to diagnose Chikungunya virus (CHIKV) infection on immunoassay instruments of the VIDAS® range.